216 related articles for article (PubMed ID: 17364879)
1. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.
Roffey SJ; Obach RS; Gedge JI; Smith DA
Drug Metab Rev; 2007; 39(1):17-43. PubMed ID: 17364879
[TBL] [Abstract][Full Text] [Related]
2. Human radiolabeled mass balance studies: objectives, utilities and limitations.
Penner N; Klunk LJ; Prakash C
Biopharm Drug Dispos; 2009 May; 30(4):185-203. PubMed ID: 19544285
[TBL] [Abstract][Full Text] [Related]
3. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?
Penner N; Xu L; Prakash C
Chem Res Toxicol; 2012 Mar; 25(3):513-31. PubMed ID: 22309195
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
5. Use of radioactive compounds and autoradiography to determine drug tissue distribution.
Solon EG
Chem Res Toxicol; 2012 Mar; 25(3):543-55. PubMed ID: 22280496
[TBL] [Abstract][Full Text] [Related]
6. Metabolites and safety: What are the concerns, and how should we address them?
Smith DA; Obach RS
Chem Res Toxicol; 2006 Dec; 19(12):1570-9. PubMed ID: 17173370
[TBL] [Abstract][Full Text] [Related]
7. Using a tritiated compound to elucidate its preclinical metabolic and excretory pathways in vivo: exploring tritium exchange risk.
Shaffer CL; Gunduz M; Thornburgh BA; Fate GD
Drug Metab Dispos; 2006 Sep; 34(9):1615-23. PubMed ID: 16790552
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment.
Sharma R; Litchfield J; Bergman A; Atkinson K; Kazierad D; Gustavson SM; Di L; Pfefferkorn JA; Kalgutkar AS
Drug Metab Dispos; 2015 Feb; 43(2):190-8. PubMed ID: 25384899
[TBL] [Abstract][Full Text] [Related]
9. New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.
Walles M; Rudolph B; Wolf T; Bourgailh J; Suetterlin M; Moenius T; Peraus G; Heudi O; Elbast W; Lanshoeft C; Bilic S
Drug Metab Dispos; 2016 Jul; 44(7):897-910. PubMed ID: 27122302
[TBL] [Abstract][Full Text] [Related]
10. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?
Obach RS; Nedderman AN; Smith DA
Xenobiotica; 2012 Jan; 42(1):46-56. PubMed ID: 21992031
[TBL] [Abstract][Full Text] [Related]
11. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
Rohatagi S; Shah B; Zhang J; Zeng Z; Kirkesseli S; Jensen BK
J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741
[TBL] [Abstract][Full Text] [Related]
12. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
[TBL] [Abstract][Full Text] [Related]
13. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.
Waters NJ; Smith SA; Olhava EJ; Duncan KW; Burton RD; O'Neill J; Rodrigue ME; Pollock RM; Moyer MP; Chesworth R
Cancer Chemother Pharmacol; 2016 Jan; 77(1):43-62. PubMed ID: 26645404
[TBL] [Abstract][Full Text] [Related]
15. Alternate strategies to obtain mass balance without the use of radiolabeled compounds: application of quantitative fluorine (19F) nuclear magnetic resonance (NMR) spectroscopy in metabolism studies.
Mutlib A; Espina R; Atherton J; Wang J; Talaat R; Scatina J; Chandrasekaran A
Chem Res Toxicol; 2012 Mar; 25(3):572-83. PubMed ID: 22292524
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary.
White RE; Evans DC; Hop CE; Moore DJ; Prakash C; Surapaneni S; Tse FL
Xenobiotica; 2013 Feb; 43(2):219-25; discussion 226-7. PubMed ID: 22803803
[TBL] [Abstract][Full Text] [Related]
17. Mass balance studies, with a focus on anticancer drugs.
Beumer JH; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2006; 45(1):33-58. PubMed ID: 16430310
[TBL] [Abstract][Full Text] [Related]
18. Recommendations on the Use of Multiple Labels in Human Mass Balance Studies.
Cuyckens F; Hvenegaard MG; Cassidy KC; Spracklin DK; James AD; Pedersen ML; Scarfe G; Wagner DS; Georgi K; Schulz SI; Schieferstein H; Bjornsdottir I; Romeo AA; Da Violante G; Blech S; Moliner P; Young GC
Drug Metab Dispos; 2024 Feb; 52(3):153-158. PubMed ID: 38216306
[TBL] [Abstract][Full Text] [Related]
19. The use of radiolabeled compounds for ADME studies in discovery and exploratory development.
Marathe PH; Shyu WC; Humphreys WG
Curr Pharm Des; 2004; 10(24):2991-3008. PubMed ID: 15379664
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
